Anavex Life Sciences Corp 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGEACTOF 1934 For the quarterly period ended:December 31, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGEACTOF 1934 For the transition period from _____to _____ Commission File Number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada98-0608404(State or other jurisdiction of(IRS Employerincorporation or organization)Identification No.) 630 5th Avenue, 20th Floor, New York, NY USA 10111(Address of principal executive offices) (Zip Code) 1-844-689-3939(Registrant’s telephone number, including area code) Securities Registered Pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). ☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes☒No Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date:92,671,758 shares of Common Stock outstanding as of February 9, 2026. PART I – FINANCIAL INFORMATION4ITEM 1. FINANCIAL STATEMENTS4ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ANDRESULTS OF OPERATIONS.19ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.36ITEM 4. CONTROLS AND PROCEDURES36PART II – OTHER INFORMATION37ITEM 1A. RISK FACTORS37ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS38ITEM 3. DEFAULTS UPON SENIOR SECURITIES38ITEM 4. MINE SAFETY DISCLOSURES38ITEM 5. OTHER INFORMATION38SIGNATURES40 PART I – FINANCIAL INFORMATION ANAVEX LIFE SCIENCES CORP. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS December 31, 2025 (Unaudited) Anavex Life Sciences Corp.Condensed Consolidated Interim Balance Sheets(in thousands, except share and per share amounts) Anavex Life Sciences Corp.Condensed Consolidated Interim Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) Anavex Life Sciences Corp.Condensed Consolidated Interim Statements of Cash Flows(in thousands, except share and per share amounts)(Unaudited) Anavex Life Sciences Corp.Condensed Consolidated Interim Statements of Changes in Stockholders’ EquityFor the three months ended December 31, 2025 and 2024(in thousands, except share and per share amounts)(Unaudited) Anavex Life Sciences Corp.Notes to the Condensed Consolidated Interim Financial StatementsDecember 31, 2025 – Page 1(Unaudited) Note 1 Business Description Business Anavex Life Sciences Corp. (“Anavex” or the “Company”) is a clinical stage biopharmaceutical company engaged in the developmentof differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need.Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for thetreatment of neurodegenerative and neurodevelopmental diseases. TheCompany’s focus is on developing innovative treatments for Alzheimer’s disease,Parkinson’s disease,schizophrenia,neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS)disorders. Note 2 Basis of Presentation These accompanying unaudited condensed consolidated interim financial statements have been prepared pursuant to the rules andregulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States ofAmerica (“U.S. GAAP”) for interim reporting. Accordingly, certain information and note disclosures normally included in the annualfinancial statements in accordance with U.S.